Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study

Table 4 Univariate and multivariate analysis for survival in 31 LM patients with wild-type EGFR

	Univariate analysis		Multivariate analysis
	HR (95%CI)	P	HR (95%CI)	P
Gender (female vs. male)	0.777 (0.328 to 1.844)	0.567
Age (< 53.5 vs. ≥53.5)	0.397 (0.153 to 1.029)	0.057	0.353 (0.125 to 0.993)	0.048
KPS (< 80 vs. ≥80)	0.654 (0.233 to 1.831)	0.419
GCS (15 vs. ≤ 14)	0.687 (0.232 to 2.033)	0.497
Concurrent brain metastasis (yes vs. no)	0.891 (0.380 to 2.088)	0.791
WBRT (yes vs. no)	0.229 (0.083 to 0.632)	0.004	0.300 (0.105 to 0.858)	0.025
Chemotherapy (yes vs. no)	0.422 (0.176 to 1.014)	0.054	0.487 (0.187 to 1.268)	0.140
Bevacizumab (yes vs. no)	0.034 (0.000 to 23.167)	0.310

Abbreviations: KPS Karnofsky performance status, GCS Glasgow coma scale, EGFR Epidermal growth factor receptor, WBRT Whole brain radiotherapy, Gy Gray, HR Hazard ratio, CI Confidence interval

ISSN: 1748-717X